企業プロフィール
Pyxis Oncology 株価・ニュース・カタリスト
- ティッカー:
- PYXS
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
3.02 USD (+0.33%)
終値
最終更新: 2026年8月17日
108M USD
時価総額
株価変動の要因
As of Aug 17, 2026, PYXS closed up 0.33% at $3.02. No new same-company headline was identified in the current news window.
企業概要
Tumor-Microenvironment ADC Company
Pyxis Oncology develops antibody-drug conjugates for difficult-to-treat cancers, with a strategy that targets structural components of the tumor microenvironment.
MICVO
Micvotabart pelidotin, or MICVO, targets extradomain-B fibronectin, a non-cellular component enriched in tumor tissue. This approach is intended to deliver a cytotoxic payload across heterogeneous tumors without relying on uniform tumor-cell antigen expression.
Head and Neck Cancer Focus
MICVO is being evaluated as monotherapy in previously treated recurrent or metastatic head and neck squamous cell carcinoma and with pembrolizumab in the first-line setting.
今後のカタリスト
- Updated Phase 1 monotherapy data for MICVO in second-line or later head-and-neck cancer in fall 2026.
- Updated Phase 1/2 data for MICVO plus pembrolizumab in first-line head-and-neck cancer in the fourth quarter of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。